Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV)
Primary Purpose
Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia
Status
Unknown status
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
offer of vaginal self collection
2nd reminder letter for Pap testing
Sponsored by
About this trial
This is an interventional prevention trial for Human Papillomavirus Infection focused on measuring vaginal self collection, human papillomavirus (hpv), cervical intraepithelial neoplasia
Eligibility Criteria
Inclusion Criteria:
- members of consenting family physicians identified through OSCAR EMR
- overdue for Pap smear testing
- have not presented for Pap smear screening after 1 reminder letter
Exclusion Criteria:
- currently attending colposcopy clinic
- institutionalized
- without a cervix
Sites / Locations
- McMaster University
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
2nd Reminder Letter
Offer of Vaginal Self Collection
Arm Description
50% of study participants who are overdue for Pap testing and do not respond to initial reminder letter will be be mailed a standard second reminder letter
50% of study participants who are overdue for Pap testing and do not respond to initial reminder letter will be selected to be mailed a second reminder letter and offer of vaginal self collection
Outcomes
Primary Outcome Measures
uptake of screening invitation
Secondary Outcome Measures
Cervical Intraepithelial Neoplasia (CIN) 3 identified
Full Information
NCT ID
NCT01095198
First Posted
March 29, 2010
Last Updated
July 19, 2011
Sponsor
McMaster University
Collaborators
Juravinski Cancer Centre Foundation, Merck Frosst Canada Ltd., Public Health Agency of Canada (PHAC)
1. Study Identification
Unique Protocol Identification Number
NCT01095198
Brief Title
Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV)
Official Title
Randomized Controlled Trial of Vaginal Self Sampling for Human Papillomavirus to Increase Cervical Cancer Screening Participation
Study Type
Interventional
2. Study Status
Record Verification Date
July 2011
Overall Recruitment Status
Unknown status
Study Start Date
April 2010 (undefined)
Primary Completion Date
November 2012 (Anticipated)
Study Completion Date
January 2013 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
McMaster University
Collaborators
Juravinski Cancer Centre Foundation, Merck Frosst Canada Ltd., Public Health Agency of Canada (PHAC)
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Up to 30% of Canadian women do not participate in Pap smear screening for cervical cancer prevention despite many being members of family practices and having access to family physicians. One reason is reluctance to undergo pelvic examination.
The investigators purpose is to determine whether the offer of vaginal self sample collection for oncogenic human papillomavirus (HPV) testing increases participation in cervical cancer screening compared to repeat reminder for Pap smear testing among female family practice members who have not previously responded to invitations for Pap testing.
Detailed Description
Pap smear screening for cervical cancer precursors has substantially reduced the incidence of invasive cervical cancer in Canada. While regular Pap screening can give up to 90% protection against cervical cancer, about 30% of Canadian women do not participate in regular screening.
Pap screening in Ontario is opportunistic. There are women who have family doctors and regularly present for other medical issues at their physician's office but forego Pap smear testing.
Numerous studies have shown that women are able to self collect vaginal samples, and that these samples can be tested for the presence of oncogenic human papillomavirus. A recent meta-analysis showed that HPV testing through physician collected samples had a sensitivity of 80%-90% for detection of cervical intraepithelial neoplasia (CIN) 2 or worse, and a specificity of 86%-95%. In comparison, a meta-analysis of self collected vaginal samples tested for HPV showed a sensitivity of 74% and a specificity of 88%.
Studies have reported that women find self collection acceptable. However, we have found that many women are more comfortable if a health care professional is available to help if needed, and so this option should be provided for self-testing.
We are proposing a randomized controlled trial to see whether (a) the offer of a vaginal self collection kit together with a second reminder for Pap testing will increase cervical screening participation amongst "never-screened" and "hard to reach" women, as compared to (b) a second reminder letter alone.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia
Keywords
vaginal self collection, human papillomavirus (hpv), cervical intraepithelial neoplasia
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1440 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
2nd Reminder Letter
Arm Type
Active Comparator
Arm Description
50% of study participants who are overdue for Pap testing and do not respond to initial reminder letter will be be mailed a standard second reminder letter
Arm Title
Offer of Vaginal Self Collection
Arm Type
Experimental
Arm Description
50% of study participants who are overdue for Pap testing and do not respond to initial reminder letter will be selected to be mailed a second reminder letter and offer of vaginal self collection
Intervention Type
Device
Intervention Name(s)
offer of vaginal self collection
Other Intervention Name(s)
flocked swab (Copan Diagnostics Inc.)
Intervention Description
Women assigned to the intervention group will be offered the opportunity to self collect a vaginal specimen for HPV testing. They will be sent a letter explaining that a study of self testing is being performed, and will invite her to participate in this study. The letter will state that, if the patient prefers, she can perform a vaginal self-test in addition to, or instead of Pap smear testing. Patients are told that they have the option of completing the self-test on their own or in their physician's office with the help of their physician or practice staff. The letter will be accompanied by a self collection kit consisting of: a swab and test tube, pamphlet (with written instructions and diagram outlining procedure), instructional DVD and return envelope.
Intervention Type
Other
Intervention Name(s)
2nd reminder letter for Pap testing
Other Intervention Name(s)
reminder letter
Intervention Description
Women in both groups will receive a letter informing them that they are due for cervical screening. This is a standard letter, and is signed by the patient's individual family physicians. It will advise the patient that this is the second reminder letter that she is due for cervical cancer screening, and will invite her to phone the physician's office to obtain an appointment for Pap testing.
Primary Outcome Measure Information:
Title
uptake of screening invitation
Time Frame
18 months
Secondary Outcome Measure Information:
Title
Cervical Intraepithelial Neoplasia (CIN) 3 identified
Time Frame
18 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
69 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
members of consenting family physicians identified through OSCAR EMR
overdue for Pap smear testing
have not presented for Pap smear screening after 1 reminder letter
Exclusion Criteria:
currently attending colposcopy clinic
institutionalized
without a cervix
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alice Lytwyn, MD, FRCPC
Organizational Affiliation
McMaster University
Official's Role
Principal Investigator
Facility Information:
Facility Name
McMaster University
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8S4L8
Country
Canada
12. IPD Sharing Statement
Learn more about this trial
Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV)
We'll reach out to this number within 24 hrs